Literature DB >> 17971612

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.

Laure A Moutouh-de Parseval, Lilia Weiss, Robert J DeLap, Robert D Knight, Jerome B Zeldis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17971612     DOI： 10.1200/JCO.2007.14.2141

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Authors:  Christine I Chen; P Leif Bergsagel; Harminder Paul; Wei Xu; Anthea Lau; Nimisha Dave; Vishal Kukreti; Ellen Wei; Chungyee Leung-Hagesteijn; Zhi Hua Li; Joseph Brandwein; Mariela Pantoja; James Johnston; Spencer Gibson; Tiffany Hernandez; David Spaner; Suzanne Trudel
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.

Authors:  Georg Aue; Jay Nelson Lozier; Xin Tian; Ann M Cullinane; Susan Soto; Leigh Samsel; Philip McCoy; Adrian Wiestner
Journal:  Am J Hematol       Date:  2011-08-02       Impact factor: 10.047

3.  Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Authors:  Danelle F James; Lillian Werner; Jennifer R Brown; William G Wierda; Jacqueline C Barrientos; Januario E Castro; Andrew Greaves; Amy J Johnson; Laura Z Rassenti; Kanti R Rai; Donna Neuberg; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

4.  Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Xavier C Badoux; Michael J Keating; Sijin Wen; William G Wierda; Susan M O'Brien; Stefan Faderl; Rachel Sargent; Jan A Burger; Alessandra Ferrajoli
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

5.  Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.

Authors:  Hideyuki Nakazawa; Sayaka Nishina; Yuto Mimura; Toru Kawakami; Yasushi Senoo; Kaoko Sakai; Ko Nakazawa; Kiyoshi Kitano
Journal:  Int J Hematol       Date:  2014-03-02       Impact factor: 2.490

Review 6.  Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Authors:  Christine I Chen
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 7.  Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Authors:  Farrukh T Awan; Amy J Johnson; Rosa Lapalombella; Weihong Hu; Margaret Lucas; Beth Fischer; John C Byrd
Journal:  Leuk Lymphoma       Date:  2010-01

8.  CCC meets ICU: redefining the role of critical care of cancer patients.

Authors:  Michael von Bergwelt-Baildon; Michael J Hallek; Alexander A Shimabukuro-Vornhagen; Matthias Kochanek
Journal:  BMC Cancer       Date:  2010-11-08       Impact factor: 4.430

9.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

10.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Authors:  Georg Aue; Ndegwa Njuguna; Xin Tian; Susan Soto; Thomas Hughes; Berengere Vire; Keyvan Keyvanfar; Federica Gibellini; Janet Valdez; Carol Boss; Leigh Samsel; J Philip McCoy; Wyndham H Wilson; Stefania Pittaluga; Adrian Wiestner
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.